Evidence map›Paper›PMID 42232612›Full record

ArticleBrain communications2026

Scalable biological-cognitive profiling for Alzheimer's disease in the population.

Karin Lohi, Aino Aaltonen, Sanna-Kaisa Herukka, Tarja Kokkola, Sari Kärkkäinen, Mia Urjansson, FinnGen, Aarno Palotie, Heiko Runz, Jaakko Kaprio and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karin LohiInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00290 Helsinki, Finland.ORCID https://orcid.org/0009-0004-1746-2823
Aino AaltonenInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00290 Helsinki, Finland.
Sanna-Kaisa HerukkaDepartment of Neurology, Institute of Clinical Medicine, University of Eastern Finland, 70210 Kuopio, Finland.
Tarja KokkolaDepartment of Neurology, Institute of Clinical Medicine, University of Eastern Finland, 70210 Kuopio, Finland.
Sari KärkkäinenDepartment of Neurology, Institute of Clinical Medicine, University of Eastern Finland, 70210 Kuopio, Finland.
Mia UrjanssonInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00290 Helsinki, Finland.
FinnGen
Aarno PalotieInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00290 Helsinki, Finland.
Heiko RunzInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00290 Helsinki, Finland.
Jaakko KaprioInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00290 Helsinki, Finland.ORCID https://orcid.org/0000-0002-3716-2455
Valtteri JulkunenDepartment of Neurology, Institute of Clinical Medicine, University of Eastern Finland, 70210 Kuopio, Finland.
Toni SaariInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00290 Helsinki, Finland.
Eero VuoksimaaInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, 00290 Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma phosphorylated tau217 has been suggested as a core biomarker for establishing a biological Alzheimer's disease diagnosis. This blood biomarker has not been studied together with scalable cognitive assessment tools in population-based samples. We investigated the prevalence of cognitive and Alzheimer's disease biomarker abnormalities and associations between plasma phosphorylated tau217 and remotely measured cognitive function in individuals without dementia. We used a population-based cross-sectional sample of 65-85-year-olds (

Indexed as

Alzheimer’s diseasediagnosisepisodic memoryplasma biomarkersemantic fluency

Identifiers

PMID42232612
PMCPMC13223580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.